Nexalin Technology, Inc. (NXL) vs Processa Pharmaceuticals, Inc. (PCSA)

A side-by-side comparison of Nexalin Technology, Inc. and Processa Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Nexalin Technology, Inc. logo
NXL
Nexalin Technology, Inc.
$4M
$4.90HealthcareDelayed quote: Oct 6, 2026, 2:05 PM EDT
Processa Pharmaceuticals, Inc. logo
PCSA
Processa Pharmaceuticals, Inc.
$4M
$1.52HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT

Total return — NXL vs PCSA

growth of $100 · dividends reinvested · last 4y
NXL -92.0% (-46.7%/yr)PCSA -99.9% (-81.0%/yr)NXL compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $1002023202420252026$8$0
NXL PCSA

NXL vs PCSA: by the numbers

  • •PCSA is the larger company ($4M vs $4M market cap).
  • •Both run net losses; PCSA's is the smaller (0.00% vs -4139.38% net margin).

Metrics side by side

Valuation

MetricNXLPCSA
P/S ratio16.56N/A
P/B ratio2.37N/A

Profitability

MetricNXLPCSA
Gross margin79.65%0.00%
Operating margin-2781.69%0.00%
Net margin-4139.38%0.00%
ROE-591.60%N/A
ROIC-600.62%N/A

Growth (annualized)

MetricNXLPCSA
Revenue CAGR (5Y)10.22%N/A
Total return CAGR (5Y)N/A-79.32%

Go deeper

Full NXL analysisFull PCSA analysisInteractive comparison tool

Dig into the metrics

Nexalin Technology ROEProcessa Pharmaceuticals ROENexalin Technology operating marginProcessa Pharmaceuticals operating marginNexalin Technology revenue growthProcessa Pharmaceuticals revenue growthNexalin Technology free cash flowProcessa Pharmaceuticals free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.